GENEVA: on the occasion of World Diabetes Day, the World Health Organisation (WHO) has decried the “vast access gaps” in the availability of insulin, a bedrock medicine for the treatment of diabetes, even 100 years after it was discovered.
In a report published to commemorate the milestone anniversary, the Geneva-based UN health agency stressed the need to cut prices and dramatically increase access to the life-saving medicine.
The report ‘Keeping the 100-year-old promise – making insulin access universal’ details the main barriers to accessing the lifesaving medicine including high prices, low availability of human insulin, a market dominated by just a few producers, and weak health systems.
Insulin is the “bedrock” of diabetes treatment, and WHO is working with countries and manufacturers to expand access to everyone who needs it. “The scientists who discovered insulin 100 years ago refused to profit from their discovery and sold the patent for just one dollar,” said Tedros Adhanom Ghebreyesus, Director-General of the UN agency. “Unfortunately, that gesture of solidarity has been overtaken by a multi-billion-dollar business that has created vast access gaps.”
WHO said for more than 60 million people living with type 2 diabetes, insulin is essential to reduce the risk of kidney failure, blindness and amputation. However, one in two people who need the medicine does not get it.
While diabetes is increasing in low and middle-income countries, their consumption of insulin has not kept up with the growing disease burden. Even though three in four people who have type 2 diabetes live outside of North America and Europe, they account for less than 40 percent of revenue from insulin sales.
The report outlines measures to improve access to insulin and related products. Actions include boosting human insulin production and supply, and diversifying manufacturing of biosimilar products to create competition and reduce prices.
WHO explained that global markets have shifted from human insulin, which can be produced at relatively low cost, to pricier synthetic insulins, which can be up to three times more expensive. The UN agency called for improved affordability by regulating prices and mark-ups through pooled procurement and greater price transparency, and promoting local manufacturing capacity in under-served regions.
At the same time, research and development (R&D) should be centred on the needs of low and middle-income countries, while increased access to insulin should be accompanied by prompt diagnosis along with access to affordable devices for injecting the medicine and monitoring blood sugar.
WHO has worked with the industry to address some of the barriers to the availability of insulin, related medicines and technologies, through holding dialogues with business associations and manufacturers.
This has resulted in several commitments by the industry, which range from developing a policy blueprint for improving access to biosimilars of insulin, to participating in WHO’s prequalification programme for insulin, glucose meters, test strips and diagnostic tools.
